ONCS - オンコセク・メディカル (OncoSec Medical Incorporated)

ONCSのニュース

   Flashy Stock: Snap Inc. (NYSE:SNAP), OncoSec Medical Incorporated (NASDAQ:ONCS)  2021/07/27 22:10:30 Stock Equity
Snap Inc. (NYSE:SNAP) with the stream of -3.37% also noticed, India OncoSec Medical Incorporated (NASDAQ:ONCS) encountered a rapid change of -3.15% in the last hour of Tuesdays trading session. Snap The post Flashy Stock: Snap Inc. (NYSE:SNAP), OncoSec Medical Incorporated (NASDAQ:ONCS) appeared first on Stocks Equity .
   The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts  2021/07/27 11:48:32 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI ) (IPOed Thursday) Arvinas, Inc. (NASDAQ: ARVN ) BioNTech SE (NASDAQ: BNTX ) ( disclosed plans to make mRNA vaccine for malaria by 2022) Cassava Sciences, Inc. (NASDAQ: SAVA ) (announced positive data for SavaDx, an investigational diagnostic/biomarker to detect Alzheimer''s disease with a simple blood test) Eli Lilly and Company (NYSE: LLY ) Moderna, Inc. (NASDAQ: MRNA ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) NanoVibronix, Inc. (NASDAQ: NAOV ) (announced first shipment of its next generation pain management device, PainShield Plus) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Sight Sciences, Inc. (NASDAQ: SGHT ) (IPOed July 15) Translate Bio, Inc. (NASDAQ: TBIO ) (moved on positive analyst action) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 26) 23andMe Holding Co. (NASDAQ: ME ) AbCellera Biologics Inc.
   OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference  2021/07/26 12:30:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, July 26, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Brian Leuthner, and Senior Vice President, Chief Clinical Development Officer, Sandra Aung,
   Analysts Recommendations to Consider: McEwen Mining Inc. (NYSE:MUX), OncoSec Medical Incorporated (NASDAQ:ONCS)  2021/07/20 22:18:06 Stock Equity
McEwen Mining Inc. (NYSE:MUX) with the stream of 0.45% also noticed, India OncoSec Medical Incorporated (NASDAQ:ONCS) encountered a rapid change of -1.02% in the last hour of Tuesdays trading session. The post Analysts Recommendations to Consider: McEwen Mining Inc. (NYSE:MUX), OncoSec Medical Incorporated (NASDAQ:ONCS) appeared first on Stocks Equity .
   The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street  2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
   OncoSec Aims to Treat Cancer with what the Body Makes Naturally — IL-12  2021/05/03 14:24:39 Benzinga
There’s no arguing that immunotherapies and immune checkpoint inhibitors have drastically improved cancer patients’ chances for survival. Checkpoint inhibitors are the most widely used immunotherapy and work by amplifying the immune system’s ability to fight cancer, with some remarkable success. However, the biotech company OncoSec (NASDAQ: ONCS ) believes that the power of immunotherapies has yet to be fully realized. Checkpoint inhibitors are intended to “block the off-switch” to the body’s T-cells to allow such cells to destroy cancers. Although it seems they’re most effective in “hot” or T-cell inflamed tumors, which have already been identified by the immune system as a target, as opposed to “cold” or immunologically devoid tumors that have not provoked an immune response. Here’s where OncoSec’s DNA gene transfer technology, TAVO™ (tavokinogene telseplasmid), comes in. “TAVO takes cold tumors, turns them hot and leverages drugs like Keytruda that allow T-cells to uncover and attack tumor cells.
   OncoSec Medical Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/11 14:02:00 Stock Market Daily
OncoSec Medical announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits  2021/02/23 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide…
   OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development  2021/02/18 13:30:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotech industry veteran with more than 15 years of experience, as Vice President of Clinical…
   OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein  2021/01/27 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only vaccine candidate to include an immunostimulatory cytokine to address COVID-19….
   OncoSec Medical Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/11 14:02:00 Stock Market Daily
OncoSec Medical announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits  2021/02/23 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide…
   OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development  2021/02/18 13:30:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotech industry veteran with more than 15 years of experience, as Vice President of Clinical…
   OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein  2021/01/27 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only vaccine candidate to include an immunostimulatory cytokine to address COVID-19….
   OncoSec Medical Closes $42.0 Million Public Offering of Common Stock  2021/01/25 21:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Jan. 25, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to…

calendar